Amanote Research
Register
Sign In
Identification of Transcriptional Subgroups in EGFR-Mutated and EGFR/KRAS Wild-Type Lung Adenocarcinoma Reveals Gene Signatures Associated With Patient Outcome
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-13-0928
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
August 12, 2013
Authors
M. Planck
S. Isaksson
S. Veerla
J. Staaf
Publisher
American Association for Cancer Research (AACR)
Related search
Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status
PLoS ONE
Multidisciplinary
P2.03-030 Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated With EGFR-TKIs
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Risk Factors of Brain Metastasis During the Course of EGFR-TKIs Therapy for Patients With EGFR-mutated Advanced Lung Adenocarcinoma
Oncotarget
Oncology
Mutation Profile of Resected EGFR‐Mutated Lung Adenocarcinoma by Next‐Generation Sequencing
Oncologist
Cancer Research
Medicine
Oncology
P3.01-002 Concurrent EGFR T790M Secondary Mutation and EMT in a Lung Adenocarcinoma Patient With EGFR TKI Drug Resistance
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients
Oncology Reports
Medicine
Cancer Research
Oncology
EGFR Inhibitors in Treatment of Lung Adenocarcinoma
Research in Oncology
P010 Relationship Between EGFR and KRAS Mutation and the Clinicopathologic Features of Early Lung Adenocarcinoma
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK Among Treatment-Naïve Patients With Advanced Lung Adenocarcinoma
PLoS ONE
Multidisciplinary
